ClinicalTrials.gg
RecruitingNCT07916272Updated Nov 4, 2026

Coronary Myocardial Bridge and Coronary Plaques on MDCT

An observational study in Myocardial Bridging and Coronary Atherosclerosis, sponsored by Sohag University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Sohag University · Observational

Updated Nov 4, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

Myocardial bridging is a condition in which a segment of a coronary artery passes through the heart muscle instead of running on its surface. This study aims to determine the prevalence of coronary myocardial bridging and investigate its relationship with coronary atherosclerotic plaques using multidetector computed tomography coronary angiography (MDCT-CA).

The study will include at least 50 patients referred for coronary CT angiography at Sohag University Hospital and New Sohag University Hospital. CT images will be evaluated to identify myocardial bridges, determine their location, measure their length and depth, and assess the presence, location, and characteristics of coronary atherosclerotic plaques.

The findings will be analyzed to investigate the association between myocardial bridging and coronary atherosclerotic plaques.

Read the detailed description

Myocardial bridging is an anatomical variant characterized by an intramyocardial course of a segment of an epicardial coronary artery. Although it is frequently considered a benign finding, several studies have suggested an association between myocardial bridging and coronary atherosclerotic plaque formation, particularly in the coronary segment proximal to the bridged segment.

This prospective observational study aims to determine the prevalence of coronary myocardial bridging using multidetector computed tomography coronary angiography (MDCT-CA) and investigate its relationship with coronary atherosclerotic plaques.

The study will be conducted at the Diagnostic and Interventional Radiology Departments of Sohag University Hospital and New Sohag University Hospital. At least 50 patients referred for coronary CT angiography will be included, without age or sex restrictions.

Coronary CT angiography examinations will be performed using 128-row or 160-row multidetector CT scanners. The imaging protocol will include coronary calcium scoring and contrast-enhanced coronary CT angiography with electrocardiographic gating.

The coronary arteries, including the right coronary artery, left main coronary artery, left anterior descending artery, and left circumflex artery, will be evaluated for the presence of myocardial bridging and coronary atherosclerotic plaques.

For each detected myocardial bridge, the following parameters will be assessed:

  • Involved coronary artery and anatomical location.
  • Length of the bridged segment, measured from its entry into the myocardium to its re-emergence onto the epicardial surface.
  • Depth of the myocardial bridge, measured as the maximum thickness of the overlying myocardial fibers.

Coronary atherosclerotic plaques will be assessed regarding their presence, location, and characteristics. The findings will subsequently be analyzed to investigate the relationship between myocardial bridging and coronary atherosclerotic plaques.

The collected data will be statistically analyzed to determine the prevalence of myocardial bridging and evaluate its association with coronary atherosclerotic plaques.

02

Conditions studied

  • Myocardial Bridging
  • Coronary Atherosclerosis

Keywords

  • Myocardial Bridge Myocardial Bridging Coronary Atherosclerotic Plaques Coronary CT Angiography Multidetector Computed Tomography MDCT
03

In context

Coronary Artery Disease

5,683 studies on the registry are indexed under Coronary Artery Disease; 960 are open to participants now.

This study's planned enrollment of 50 is below the median of 334 across 1,979 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Sohag University is the lead sponsor of 1,225 studies on the registry; 632 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of patients referred to the Diagnostic and Interventional Radiology Department at Sohag University Hospital and New Sohag University Hospital to undergo coronary CT angiography. At least 50 patients of both sexes, without age restrictions, will be included in this prospective observational study to assess the prevalence of coronary myocardial bridging and its relationship with coronary atherosclerotic plaques.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients referred to the Radiology Department of Sohag University Hospital and New Sohag University Hospital for coronary CT angiography.

Exclusion criteria

Exclusion Criteria:

  • Patients with contraindications to CT examination due to radiation-related risks.
  • Patients with known allergy to iodinated contrast media or impaired renal function (serum creatinine > 1.5 mg/dL or estimated glomerular filtration rate \< 30 mL/min).
  • Patients with heart rate or rhythm incompatible with electrocardiographically gated scanning (heart rate > 70 beats/min or uncontrolled atrial fibrillation).
  • Patients with an Agatston calcium score > 400.
  • Uncooperative patients or those who do not provide informed consent
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of participants with Prevalence of Coronary Myocardial Bridging

    Determination of the prevalence of coronary myocardial bridging among patients undergoing multidetector computed tomography coronary angiography (MDCT-CA), based on the identification of intramyocardial coronary artery segments.

    Time frame: Day 1 (At the time of coronary CT angiography examination"

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rovera C, Moretti C, Bisanti F, De Zan G, Guglielmo M. Myocardial Bridging: Review on the Role of Coronary Computed Tomography Angiography. J Clin Med. 2023 Sep 13;12(18):5949. doi: 10.3390/jcm12185949. PubMed 37762890 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers to maintain patient confidentiality and protect personal information. Study results may be disseminated in scientific publications in aggregate form without identifying individual participants.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.

Of 728 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 8 months is below that.

Counting every sponsor, half of 860 studies reached it within 42 months; a quarter within 21 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 4, 2026
StartActual
Oct 20, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07916272
Lead sponsor
Sohag University
Responsible party
Abdelaziz Aly Mohamed (Senior Resident in Diagnostic and Interventional Radiology, Sohag University) — Principal investigator
First posted
Nov 4, 2026
Start date
Oct 20, 2026
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion